In Reply—Additional Safety Considerations Before Prescribing Opioids to Manage Restless Legs Syndrome

Michael H. Silber; Philip M. Becker; Mark J. Buchfuhrer; Christopher J. Earley; William G. Ondo; Arthur S. Walters; John W. Winkelman

doi:10.1016/j.mayocp.2018.03.021

In Reply—Additional Safety Considerations Before Prescribing Opioids to Manage Restless Legs Syndrome

Michael H. Silber, Philip M. Becker, Mark J. Buchfuhrer, Christopher J. Earley, William G. Ondo, Arthur S. Walters, John W. Winkelman

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	955-956
Number of pages	2
Journal	Mayo Clinic Proceedings
Volume	93
Issue number	7
DOIs	https://doi.org/10.1016/j.mayocp.2018.03.021
State	Published - Jul 2018

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/j.mayocp.2018.03.021

Cite this

@article{6eeb569f91344799ac423762a90517ec,

title = "In Reply—Additional Safety Considerations Before Prescribing Opioids to Manage Restless Legs Syndrome",

author = "Silber, {Michael H.} and Becker, {Philip M.} and Buchfuhrer, {Mark J.} and Earley, {Christopher J.} and Ondo, {William G.} and Walters, {Arthur S.} and Winkelman, {John W.}",

note = "Funding Information: Potential Competing Interests: Dr Silber receives royalties from UpToDate and payment for development of educational presentations from the American Academy of Sleep Medicine and American Academy of Neurology. Dr Buchfuhrer receives consultancy fees from Xenoport; receives payment for lectures including service on speakers bureaus from UCB Pharma, Arbor Pharmaceuticals, and Xenoport; owns stock/stock options in Sensory Medical. Dr Earley receives grants from Luitpold Pharmaceuticals and honorarium from the American Academy of Sleep Medicine. Dr Ondo receives grants from Luitpold Pharmaceuticals and payment for lectures including service on speakers bureaus from UCB Pharma. Dr Walters receives grants from Mundipharma, Arbor Pharmaceuticals, National Institutes of Health, UCB Pharma, and Xenoport. Dr Winkelman receives consultancy fees from Merck and Flex Pharma and grants from Restless Legs Syndrome Foundation, Luitpold Pharmaceuticals, NeuroMetrix, National Institute of Mental Health, and UCB Pharma; he is an employee of Massachusetts General Hospital. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2018",

month = jul,

doi = "10.1016/j.mayocp.2018.03.021",

language = "English (US)",

volume = "93",

pages = "955--956",

journal = "Mayo Clinic Proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "7",

}

TY - JOUR

T1 - In Reply—Additional Safety Considerations Before Prescribing Opioids to Manage Restless Legs Syndrome

AU - Silber, Michael H.

AU - Becker, Philip M.

AU - Buchfuhrer, Mark J.

AU - Earley, Christopher J.

AU - Ondo, William G.

AU - Walters, Arthur S.

AU - Winkelman, John W.

N1 - Funding Information: Potential Competing Interests: Dr Silber receives royalties from UpToDate and payment for development of educational presentations from the American Academy of Sleep Medicine and American Academy of Neurology. Dr Buchfuhrer receives consultancy fees from Xenoport; receives payment for lectures including service on speakers bureaus from UCB Pharma, Arbor Pharmaceuticals, and Xenoport; owns stock/stock options in Sensory Medical. Dr Earley receives grants from Luitpold Pharmaceuticals and honorarium from the American Academy of Sleep Medicine. Dr Ondo receives grants from Luitpold Pharmaceuticals and payment for lectures including service on speakers bureaus from UCB Pharma. Dr Walters receives grants from Mundipharma, Arbor Pharmaceuticals, National Institutes of Health, UCB Pharma, and Xenoport. Dr Winkelman receives consultancy fees from Merck and Flex Pharma and grants from Restless Legs Syndrome Foundation, Luitpold Pharmaceuticals, NeuroMetrix, National Institute of Mental Health, and UCB Pharma; he is an employee of Massachusetts General Hospital. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2018/7

Y1 - 2018/7

UR - http://www.scopus.com/inward/record.url?scp=85048960397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048960397&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2018.03.021

DO - 10.1016/j.mayocp.2018.03.021

M3 - Letter

C2 - 29976378

AN - SCOPUS:85048960397

SN - 0025-6196

VL - 93

SP - 955

EP - 956

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

IS - 7

ER -

In Reply—Additional Safety Considerations Before Prescribing Opioids to Manage Restless Legs Syndrome

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this